Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical characteristics of women with and without BRCAfounder mutations

From: A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

Variable No BRCA founder mutation (n = 440) BRCA1 founder mutation (n = 43) P (BRCA1 versus no founder mutation)* BRCA2 founder mutation (n = 14) P (BRCA2 versus no founder mutation)*
Age at diagnosis (years)      
   < 50 135 (31%) 30 (70%) < 0.0001 4 (29%) NS
   ≥ 50 305 (69%) 13 (30%)   10 (71%)  
Tumor size      
   T1 324 (74%) 29 (67%) NS 8 (57%) NS
   T2 97 (22%) 11 (26%)   4 (29%)  
   Unknown 19 (4%) 3 (7%)   2 (14%)  
Nodal involvement      
   Present 149 (34%) 18 (42%) NS 6 (43%) NS
   Absent 262 (60%) 23 (53%)   6 (43%)  
   Unknown 29 (6%) 2 (5%)   2 (14%)  
Estrogen receptor      
   Positive 197 (45%) 6 (14%) < 0.0001 7 (50%) NS
   Negative 98 (22%) 27 (63%)   3 (21%)  
   Unknown 145 (33%) 10 (23%)   4 (29%)  
Chemotherapy      
   Yes 156 (35%) 24 (56%) 0.02 7 (50%) NS
   No 257 (58%) 17 (40%)   7 (50%)  
   Unknown 27 (10%) 2 (4%)   0 (0%)  
Tamoxifen      
   Yes 190 (43%) 10 (23%) 0.01 9 (64%) NS
   No 203 (46%) 30 (70%)   5 (36%)  
   Unknown 47 (11%) 3 (7%)   0 (0%)  
  1. *Cases in which the characteristic of interest is unknown are not included in the comparisons. Woman with both BRCA1 and BRCA2 founder mutations are included in both groups, hence the total number women listed here is 497.